Novartis has broken ground on a new 46,000-square foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility was announced in February 2026 as part of Novartis’ $23-billion US investment plan. 

The site will be the company’s first Texas‑based manufacturing facility and will be the company’s fifth RLT site in the US. The site is expected to become fully operational in 2028 and will manufacture cancer treatments.  

The site will add to Novartis’ US RTL manufacturing network in the US. The company has ongoing expansions of its existing sites in Milburn, New Jersey and Indianapolis, Indiana, and opened a new RTL facility in Carlsbad, California, last November (November 2025). The company is also adding a new RTL site in Winter Park, Florida. That 35,000-square-foot facility is slated to come online by 2029.  

Expanding RTL manufacturing in the US is one part of Novartis’ $23-billion US investment plan. In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint as part of the company’s broader effort to manufacture all key medicines for US patients in the US. In addition to the expansion of its RTL manufacturing network in the US, other key investments include:  

• April (April 2026): Announced a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient manufacturing for solid dosage tablets, capsules and RNA therapeutics across oncology, immunology, and cardiovascular, renal and metabolic diseases; 

• February (February 2026): Broke ground on a new 466,000-square-foot biomedical research center in San Diego, California, expanding its US research presence alongside Cambridge, Massachusetts, and supporting discovery across disease areas, including neuroscience and oncology; and

• December 2025: Broke ground on a flagship manufacturing hub in North Carolina, adding solid dosage tablet and capsule and biologics production and sterile packaging for treatments across oncology, immunology, neuroscience, and cardiovascular, renal and metabolic disease. 

Source: Novartis